Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study

#1007

Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.

Aim(s): To analyze short-term changes in vascular function caused by E in patients with pNETs.

Materials and methods: In four patients with advanced E-treated pNETs, at baseline (B), after one month (T1) and 2 months (T2), we evaluated: central blood pressures (CBP), Augmentation Index (AIx) and Pulse Wave Velocity (PWV) using Sphygmocor as markers of arterial stiffness and arteriolar resistance, microcircular perfusion flow (PF) and vasodilatation response to ischemia (VDRI) using Laser-Doppler Flowmetry as a marker of endothelial function.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cingarlini S

Authors: Vallerio P, Cingarlini S, Trentin C, Grego E, D'Onofrio M,

Keywords: everolimus, endothelial dysfunction,